Investigational drug · Phase 2
ESG206
Also called: ESG206-2
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Lupus Erythematosus (SLE), Immune Thrombocytopenia (ITP), Primary Sjögren Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "ESG206"
First trial start
2025
May 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ESG206", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Lupus Erythematosus (SLE)
- Immune Thrombocytopenia (ITP)
- Primary Sjögren Syndrome
Approved drugs for the same conditions: Immune thrombocytopenia · Lupus (SLE) · Hematology and blood cancers · Cardiovascular and metabolic · Immunology and inflammation · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ESG206" as an intervention, largest first.
Shanghai Escugen Biotechnology Co., LtdIndustry
NCT06853444 · 84 participants (planned) · Start May 8, 2025 · Primary completion Mar 31, 2026
Drug: ESG206; ESG206 and 2 more · For: Immune Thrombocytopenia (ITP)
Sites: Jinan, China
- A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus ErythematosusNot yet recruiting
Shanghai Escugen Biotechnology Co., LtdIndustry
NCT07760155 · 40 participants (planned) · Start Sep 1, 2026 · Primary completion Mar 31, 2028
Drug: ESG206; ESG206 and 1 more · For: Systemic Lupus Erythematosus (SLE)
Sites: Shenzhen, China; Zhongshan, China; Guilin, China · 20 sites in all
- A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren SyndromeNot yet recruiting
Shanghai Escugen Biotechnology Co., LtdIndustry
NCT07375524 · 40 participants (planned) · Start Mar 1, 2026 · Primary completion Dec 31, 2027
Drug: ESG206; ESG206 and 1 more · For: Primary Sjögren Syndrome
Sites: Beijing, China; Xiamen, China; Guilin, China · 21 sites in all
Shanghai Escugen Biotechnology Co., LtdIndustry
NCT05822843 · 13 participants · Start Aug 2, 2023 · Primary completion Jan 22, 2025
Drug: ESG206 · For: B-cell Lymphoid Malignancies
Sites: Beijing, China
Shanghai Escugen Biotechnology Co., LtdIndustry
NCT05263739 · 0 participants · Start Dec 2025 · Primary completion Aug 2026
Drug: ESG206 · For: B-cell Lymphoid Malignancies
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Systemic Lupus Erythematosus (SLE)
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- EnpatoranM5049, M5049 dosePhase 35 trials
EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
- LitifilimabBIIB059Phase 35 trials
Biogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Lupus Erythematosus, Systemic
- SCTC21CPhase 34 trials
Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)
- SG301Phase 33 trials
Hangzhou Sumgen Biotech Co., Ltd. · Systemic Lupus Erythematosus (SLE), Relapsed/Refractory Multiple Myeloma, Antibody Mediated Rejection
- Descartes-08Phase 24 trials
Cartesian Therapeutics · Myasthenia Gravis, Generalized, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)
- BCMA-CD19-IL-15Phase 22 trials
iCell Gene Therapeutics · Inflammatory Bowel Diseases (IBD), Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
- C-CAR168Phase 22 trials
AbelZeta Inc. · Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.